FindTrial
Sign In

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00099879
Enrollment
Unknown
Registered
2004-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Brief summary

The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Interventions

DRUGBMS-275183

Sponsors

Bristol-Myers Squibb
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions * ECOG Performance Status of 0-2

Exclusion criteria

* Inability to swallow capsules * Recent significant cardiovascular disease * Woman who are pregnant or breastfeeding

Countries

Belgium, France, Italy, Netherlands, Spain, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026